Estimation of prostate cancer risk on the basis of total and free prostate-specific antigen, prostate volume and digital rectal examination

European Urology

Volumn 41, Issue 6, 2002, Pages 619-627

  Finne, Patrik ^a   Auvinen, Anssi ^b   Aro, Jussi ^a   Juusela, Harri ^c   Määttänen, Liisa ^d   Rannikko, Sakari ^a   Hakama, Matti ^b,d   Tammela, Teuvo L J ^e   Stenman, Ulf Håkan ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF TAMPERE   (Finland)

^c JORVI HOSPITAL   (Finland)

^d FINNISH CANCER REGISTRY   (Finland)

^e TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Prostate biopsy; Prostate cancer; Risk estimation; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EARLY DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; ORGAN SIZE; PALPATION; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT;

AGED; BIOPSY; FALSE POSITIVE REACTIONS; HUMANS; LOGISTIC MODELS; MALE; MASS SCREENING; MIDDLE AGED; NEURAL NETWORKS (COMPUTER); PALPATION; PROBABILITY; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECTUM; RISK; TUMOR MARKERS, BIOLOGICAL;

EID: 0036624927     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(02)00179-3     Document Type: Article

References (30)

1. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49:33-64.
2. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-61.
3. Stenman U-H, Leinonen J, Zhang W-M, Finne P. Prostate-specific antigen. Semin Cancer Biol 1999;9:83-93.
4. Määttänen L, Auvinen A, Stenman UH, Tammela T, Rannikko S, Aro J, et al. Three-year results of the Finnish prostate cancer screening trial. J Natl Cancer Inst 2001;93:552-3.
5. Smith RA, Mettlin CJ, Davis KJ, Eyre H. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin 2000;50:34-49.
6. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate-specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men. J Urol 1994;151:1283-90.
7. Schröder FH, van der Maas P, Beemsterboer P, Kruger AB, Hoedemaeker R, Rietbergen J, Kranse R. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 1998;90:1817-23.
8. Määttänen L, Auvinen A, Stenman UH, Rannikko S, Tammela T, Aro J, et al. European randomized study of prostate cancer screening: First-year results of the Finnish trial. Br J Cancer 1999;79:1210-4.
9. Carlson GD, Calvanese CB, Partin AW. An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: Results on 4298 cases. Urology 1998;52:455-61.
10. Virtanen A, Gomari M, Kranse R, Stenman UH. Estimation of prostate cancer probability by logistic regression: Free and total prostate-specific antigen, digital rectal examination, and heredity are significant variables. Clin Chem 1999;45:987-94.
11. Kranse R, Beemsterboer P, Rietbergen J, Habbema D, Hugosson J, Schröder FH. Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region). Prostate 1999;39:316-22.
12. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadler RB. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995;274:1214-20.
13. Partin AW, Catalona WJ, Southwick PC, Subong EN, Gasior GH, Chan DW. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: Influence of total PSA, prostate volume, and age. Urology 1996;48:55-61.
14. Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, Cooner WH. Prostate-specific antigen density: A means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992;147:815-6.
15. Bangma CH, Rietbergen JB, Kranse R, Blijenberg BG, Petterson K, Schröder FH. The free-to-total prostate-specific antigen ratio improves the specificity of prostate-specific antigen in screening for prostate cancer in the general population. J Urol 1997;157:2191-6.
16. Finne P, Finne R, Auvinen A, Juusela H, Aro J, Määttänen L, et al. Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network. Urology 2000;56:418-22.
17. Finne P, Finne R, Stenman UH. Neural network analysis of clinicopathological factors in urological disease: A critical evaluation of available techniques. Br J Urol Int 2001;88:825-31.
18. Blijenberg BG, Bangma CH, Kranse R, Eman I, Schröder FH. Analytical evaluation of the new Prostatus PSA Free/Total assay for prostate-specific antigen as part of a screening study for prostate cancer. Eur J Clin Chem Clin Biochem 1997;35:111-4.
19. Terris MK, Stamey TA. Determination of prostate volume by transrectal ultrasound. J Urol 1991;145:984-7.
20. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: Wiley, 1989.
21. Djavan B, Remzi M, Zlotta A, Seitz C, Snow P, Marberger M. Novel artificial neural network for early detection of prostate cancer. J Clin Oncol 2002;20:921-9.
22. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6-4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997;277:1452-5.
23. Arcangeli CG, Humphrey PA, Smith DS, Harmon TJ, Shepherd DL, Keetch DW, Catalona WJ. Percentage of free serum prostate-specific antigen as a predictor of pathologic features of prostate cancer in a screening population. Urology 1998;51:558-64.
24. Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. Serum concentrations of prostate-specific antigen and its complex with α 1-antichymotrypsin before diagnosis of prostate cancer. Lancet 1994;344:1594-8.
25. Catalona WJ, Southwick PC, Slawin KM, Partin AW, Brawer MK, Flanigan RC, et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 2000;56:255-60.
26. Stenman U-H, Leinonen J, Zhang W-M, Finne P, Wu P. The clinical importance of free prostate-specific antigen (PSA). Curr Opin Urol 1998;8:393-9.
27. Haese A, Graefen M, Noldus J, Hammerer P, Huland E, Huland H. Prostatic volume and ratio of free-to-total prostate-specific antigen in patients with prostatic cancer or benign prostatic hyperplasia. J Urol 1997;158:2188-92.
28. Optenberg SA, Clark JY, Brawer MK, Thompson IM, Stein CR, Friedrichs P. Development of a decision-making tool to predict risk of prostate cancer: The cancer of the prostate risk index (CAPRI) test. Urology 1997;50:665-72.
29. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA 1998;279:1542-7.
30. Djavan B, Zlotta A, Remzi M, Ghawidel K, Basharkhah A, Schulman CC, Marberger M. Optimal predictors of prostate cancer on repeat prostate biopsy: A prospective study of 1,051 men. J Urol 2000;163:1144-8.